Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista Colombiana de Cardiología
Print version ISSN 0120-5633
Abstract
RUIZ-MORI, Enrique; AYALA-BUSTAMANTE, Leonor; BURGOS-BUSTAMANTE, Jorge and PACHECO ROMAN, Cristian. Chemotherapy-induced bradycardia in oncology patients. Rev. Colomb. Cardiol. [online]. 2019, vol.26, n.5, pp.272-278. ISSN 0120-5633. https://doi.org/10.1016/j.rccar.2018.08.001.
Introduction:
There are daily reports of the toxic effects of chemotherapy on the heart, among them are the arrhythmias. However, there are very few publications on bradycardia caused by anti-neoplastic treatment.
Objective:
To describe and analyse the presence of post-chemotherapy bradycardia in the oncology patient.
Materials and methods:
A non-experimental, descriptive and retrospective study was conducted on patients seen during the year 2017 in a Cardiology Department due to post-chemotherapy bradycardia.
Results:
A total of 59 patients were evaluated, of whom 31 (52.5%) were males and 28 (47.5%) women, and with a median age of 42 years. The median heart rate was 46 beats per minute. The bradycardia was more common in acute myelocytic leukaemia (25.42%), followed by acute lymphoblastic leukaemia (20.34%). It was asymptomatic in 88.31% of cases. The chemotherapy drugs associated with bradycardia in acute myelocytic leukaemia were cytarabine in combination with daunorubicin, whilst in acute lymphoblastic leukaemia they were vincristine in combination with daunorubicin. A prolonged QTc interval was present in 12 (20.34%) of cases. The time between the chemotherapy and the onset of bradycardia was 24 to 48 hours in 35.6%, and the recovery of the heart rate was between 24 and 48 hours in 61.02%.
Conclusions:
Sinus bradycardia as an adverse effect of chemotherapy is more frequent in acute myelocytic leukaemia, whilst the most common anti-neoplastic drugs associated with bradycardia were cytarabine and daunorubicin.
Keywords : Bradycardia; Arrhythmias; Chemotherapy; Cardiovascular adverse effect; Cardio-oncology.